13F reference period
Q3 2026
Security Snapshot
Eikon Therapeutics, Inc. - COMMON STOCK (EIKN) Institutional Ownership
CUSIP: 282564103
13F Institutional Holders and Ownership History from Q1 2026 to Q3 2026
Institutions Reporting
41
Shares (Excl. Options)
8.23M
Full value: 8,232,611 · shares · 30 Sep 2026Price
$8.04
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- EIKN on Nasdaq
- All holders as of 30 Sep 2026
- Q3 2026
- Total 13F shares
- 8,232,611
- Total 13F value
- $65,613,959
- Portfolio coverage rank
- 0%
- Share change
- +1,188,760
- Value change
- +$8,760,017
- Number of holders
- 41
- Shares outstanding
- 54,119,137
- SEC-reported price per share
- $7.33
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- EIKN - Eikon Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 282564103.
- 41 institutions reported positions in Q3 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 77 to 41 between Q2 2026 and Q3 2026.
- SEC-reported value moved from to
$344.12M
Full value: $344,120,783 · USD · 30 Jun 2026.$65.61M
Full value: $65,613,959 · USD · 30 Sep 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 41 institutions filings for Q3 2026.
Security key
282564103
13F reference period
Q3 2026
13F holders
41
13D/G owners
6
CIK / CUSIP context first
Open Q3 2026 holders
EIKN full holder history
Eikon Therapeutics, Inc. SEC filings
Eikon Therapeutics, Inc. company facts
Eikon Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 282564103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
EIKN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 10% | +11% | $49,350,159 | +$4,704,639 | 5,520,152 | +11% | FMR LLC | 30 Sep 2026 |
| Foresite Capital Fund IV, L.P. | 7.7% | 4,148,519 | James B. Tananbaum | 04 Feb 2026 | ||||
| BlackRock Portfolio Management LLC | 5.5% | $29,456,850 | 3,002,737 | BlackRock Portfolio Management LLC | 31 Mar 2026 | |||
| PERLMUTTER ROGER M | 5.2% | $28,555,598 | 2,893,171 | PERLMUTTER ROGER M | 04 Feb 2026 | |||
| Innovation Endeavors III LP | 5% | $26,878,241 | 2,723,226 | Innovation Endeavors III LP | 31 Mar 2026 | |||
| Abu Dhabi Investment Authority | 2.1% | -62% | $10,255,414 | -$14,926,009 | 1,147,138 | -59% | Abu Dhabi Investment Authority | 30 Sep 2026 |
As of 30 Sep 2026,
41
institutional investors reported holding
shares of
Eikon Therapeutics, Inc. - COMMON STOCK (EIKN).
This represents
15%
of the company’s total
outstanding shares.
8.23M
Full value: 8,232,611 · shares · 30 Sep 202654.12M
Full value: 54,119,137 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
15%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Merck & Co., Inc. | 3.1% | 1,666,666 | 0% | 1.6% | $13,399,995 |
| Capital World Investors | 2.2% | 1,175,944 | 0% | 0% | $9,454,590 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.9% | 1,015,513 | +10% | 0% | $8,164,725 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.4% | 754,499 | +35% | 0% | $6,067,433 |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 1.2% | 635,131 | 0.08% | $5,106,453 | |
| STATE STREET CORP | 1.1% | 608,838 | +72% | 0% | $4,895,058 |
| SOROS CAPITAL MANAGEMENT LLC | 0.9% | 484,672 | 0% | 2.1% | $3,896,763 |
| FRANKLIN TEMPLETON INC | 0.65% | 350,000 | 0% | 0% | $2,236,500 |
| Affinity Asset Advisors, LLC | 0.55% | 298,001 | +204% | 0.14% | $2,395,928 |
| MORGAN STANLEY | 0.46% | 247,112 | +1954% | 0% | $1,986,781 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.41% | 223,019 | +50% | 0% | $1,793,073 |
| VANGUARD FIDUCIARY TRUST CO | 0.37% | 202,239 | +36% | 0% | $1,626,002 |
| BNP PARIBAS FINANCIAL MARKETS | 0.25% | 137,415 | 0% | $1,104,817 | |
| ALPS ADVISORS INC | 0.13% | 71,255 | +30% | 0% | $572,890 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 0.12% | 63,830 | 0% | $513,193 | |
| Invesco Ltd. | 0.09% | 51,158 | +0.51% | 0% | $411,310 |
| EntryPoint Capital, LLC | 0.09% | 47,943 | 0.11% | $385,462 | |
| DCF Advisers, LLC | 0.06% | 33,792 | 0.08% | $271,688 | |
| Quadrature Capital Ltd | 0.05% | 28,399 | 0% | $228,328 | |
| DEUTSCHE BANK AG\ | 0.05% | 27,230 | +27% | 0% | $218,929 |
| Y-Intercept (Hong Kong) Ltd | 0.04% | 20,297 | 0% | $163,188 | |
| ProShare Advisors LLC | 0.03% | 15,757 | -47% | 0% | $126,687 |
| Entropy Technologies, LP | 0.03% | 15,500 | 0% | $124,620 | |
| Vanguard Global Advisers, LLC | 0.02% | 11,991 | +41% | 0% | $96,408 |
| Jump Financial, LLC | 0.02% | 10,400 | -42% | 0% | $83,616 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
3
Headline period
Q3 2026
Rows shown
1-3 of 3